{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:31:09Z","timestamp":1785583869541,"version":"3.56.0"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Autosomal-dominant polycystic kidney disease is a clinically significant disorder associated with progressive renal impairment. In these patients, cyst infection is an important but variably occurring complication, and optimal antibiotic selection remains challenging owing to the limited available evidence and restricted antibiotic penetration into cysts. An 81-year-old Japanese man with autosomal-dominant polycystic kidney disease undergoing maintenance hemodialysis presented with fever and a suspected cyst infection. Blood cultures showed the fluoroquinolone-resistant\n                    <jats:italic toggle=\"yes\">Enterococcus faecium<\/jats:italic>\n                    . Vancomycin was contraindicated due to allergy, and teicoplanin was ineffective. Oral linezolid was initiated, resulting in clinical improvement. However, treatment was discontinued after 15\u2009days of therapy (on hospital day 27) because of grade 1 thrombocytopenia. This case contributes to the limited clinical evidence in this field and highlights the potential role of linezolid in the management of\n                    <jats:italic toggle=\"yes\">Enterococcus faecium<\/jats:italic>\n                    suspected cyst infections in autosomal-dominant polycystic kidney disease when glycopeptides are ineffective or contraindicated.\n                  <\/jats:p>","DOI":"10.1177\/2050313x261460553","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:12:06Z","timestamp":1783134726000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Linezolid as a potential alternative to glycopeptide in treating\n                    <i>Enterococcus faecium<\/i>\n                    suspected cyst infection in a hemodialysis patient with autosomal-dominant polycystic kidney disease: A case report"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-510X","authenticated-orcid":false,"given":"Takahito","family":"Inagaki","sequence":"first","affiliation":[{"name":"Division of Hospital Pharmaceutics, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Shinagawa-ku, Tokyo, Japan"},{"name":"Department of Pharmacy, Showa Medical University Hospital, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2968-2102","authenticated-orcid":false,"given":"Mai","family":"Otsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kanagawa Prefectural Keiyukai Keiyu Hospital, Nishi-ku, Yokohama City, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-2016","authenticated-orcid":false,"given":"Akitoshi","family":"Takuma","sequence":"additional","affiliation":[{"name":"Division of Hospital Pharmaceutics, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Shinagawa-ku, Tokyo, Japan"},{"name":"Department of Pharmacy, Izumi Memorial Hospital, Adachi-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9856-0097","authenticated-orcid":false,"given":"Kenji","family":"Momo","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Cornec-Le Gall E Alam A Perrone RD. Autosomal dominant polycystic kidney disease. Lancet 2019; 393(10174): 919\u2013935. https:\/\/doi.org\/10.1016\/s0140-6736(18)32782-X","DOI":"10.1016\/S0140-6736(18)32782-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Nishio S Tsuchiya K Nakatani S et al. A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020. Clin Exp Nephrol 2021; 25(12): 1292\u20131302. https:\/\/doi.org\/10.1007\/s10157-021-02097-6","DOI":"10.1007\/s10157-021-02097-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Kobayashi M Kamai T. Epidemiological estimates and early detection of polycystic kidney disease by ultrasonographic assessment in Japan. Med Ultrason 2022; 24(2): 140\u2013145. https:\/\/doi.org\/10.11152\/mu-3330","DOI":"10.11152\/mu-3330"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Suwabe T Araoka H Ubara Y et al. Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics. Eur J Clin Microbiol Infect Dis 2015; 34(7): 1369\u20131379. https:\/\/doi.org\/10.1007\/s10096-015-2361-6","DOI":"10.1007\/s10096-015-2361-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Lantinga MA Casteleijn NF Geudens A et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant 2017; 32(1): 144\u2013150. https:\/\/doi.org\/10.1093\/ndt\/gfv452","DOI":"10.1093\/ndt\/gfv452"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Hanai Y Takahashi Y Niwa T et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother 2022; 77(4): 869\u2013879. https:\/\/doi.org\/10.1093\/jac\/dkab499","DOI":"10.1093\/jac\/dkab499"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Freites-Martinez A Santana N Arias-Santiago S et al. Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 2021; 112(1): 90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","DOI":"10.1016\/j.adengl.2019.05.021"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Suwabe T Ubara Y Higa Y et al. Infected hepatic and renal cysts: differential impact on outcome in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2009; 112(3): c157\u2013c163. https:\/\/doi.org\/10.1159\/000214211","DOI":"10.1159\/000214211"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Torres VE Ahn C Barten TRM et al. KDIGO 2025 clinical practice guideline for the evaluation management and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int 2025; 107(2): 234\u2013254. https:\/\/doi.org\/10.1016\/j.kint.2024.07.010.","DOI":"10.1016\/j.kint.2024.07.010"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Treglia G Albano D Rizzo A et al. Performance of [18F]FDG PET\/CT in diagnosing cyst infections in patients with autosomal dominant polycystic kidney disease: a systematic review and a bivariate meta-analysis. Diagnostics 2024; 14(15): 1603. https:\/\/doi.org\/10.3390\/diagnostics14151603","DOI":"10.3390\/diagnostics14151603"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Sall\u00e9e M Rafat C Zahar JR et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4(7): 1183\u20131189. https:\/\/doi.org\/10.2215\/CJN.01870309","DOI":"10.2215\/CJN.01870309"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Rosselli Del Turco E Bartoletti M Dahl A et al. How do I manage a patient with enterococcal bacteraemia?. Clin Microbiol Infect 2021; 27(3): 364\u2013371. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.029","DOI":"10.1016\/j.cmi.2020.10.029"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Yamaguchi R Yamamoto T Okamoto K et al. Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study. J Antimicrob Chemother 2023; 78(5): 1231\u20131240. https:\/\/doi.org\/10.1093\/jac\/dkad079","DOI":"10.1093\/jac\/dkad079"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Bennett WM Elzinga L Pulliam JP et al. Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis 1985; 6(6): 400\u2013404. https:\/\/doi.org\/10.1016\/s0272-6386(85)80102-5","DOI":"10.1016\/S0272-6386(85)80102-5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Chow KM Chan CY Leung CB et al. Vancomycin concentrations in autosomal dominant polycystic kidney disease. Clin Infect Dis 2005; 40(1): 205. https:\/\/doi.org\/10.1086\/426689","DOI":"10.1086\/426689"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Echeverria-Esnal D Sorli L Prim N et al. Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score matched comparative study. Int J Antimicrob Agents 2019; 54(5): 572\u2013578. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.018","DOI":"10.1016\/j.ijantimicag.2019.08.018"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Bassetti M Baguneid M Bouza E et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014; 20(suppl 4): 3\u201318. https:\/\/doi.org\/10.1111\/1469-0691.12463","DOI":"10.1111\/1469-0691.12463"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Liu X Aoki M Osa S et al. Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis. BMC Pharmacol Toxicol 2022; 23(1): 89. https:\/\/doi.org\/10.1186\/s40360-022-00628-9","DOI":"10.1186\/s40360-022-00628-9"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"Tsuji Y Hiraki Y Mizoguchi A et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008; 14(2): 156\u2013160. https:\/\/doi.org\/10.1007\/s10156-008-0587-2","DOI":"10.1007\/s10156-008-0587-2"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Matsumoto K Takeda Y Takeshita A et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents 2009; 33(1): 98\u201399. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.07.002","DOI":"10.1016\/j.ijantimicag.2008.07.002"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Smith TT Tamma PD Do TB et al. Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium. Diagn Microbiol Infect Dis 2018; 91(2): 161\u2013163. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.01.027","DOI":"10.1016\/j.diagmicrobio.2018.01.027"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261460553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X261460553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261460553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:46:18Z","timestamp":1783309578000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X261460553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["10.1177\/2050313X261460553"],"URL":"https:\/\/doi.org\/10.1177\/2050313x261460553","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X261460553"}}